Ubs Group Ag Aura Biosciences, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Aura Biosciences, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 21,986 shares of AURA stock, worth $180,285. This represents 0.0% of its overall portfolio holdings.

Number of Shares

21,986

Previous 14,265 54.13%

Holding current value

$180,285

Previous $107,000 82.24%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.9 - $10.36 $53,274 - $79,989	7,721 Added 54.13%	21,986 $195,000
Q2 2024 Aug 13, 2024	SELL	$6.81 - $7.89 $152,414 - $176,586	-22,381 Reduced 61.07%	14,265 $107,000
Q1 2024 May 13, 2024	BUY	$7.09 - $9.24 $39,590 - $51,596	5,584 Added 17.98%	36,646 $287,000
Q4 2023 Feb 09, 2024	BUY	$7.02 - $11.98 $212,965 - $363,437	30,337 Added 4184.41%	31,062 $275,000
Q3 2023 Nov 09, 2023	BUY	$8.97 - $12.38 $6,503 - $8,975	725 New	725 $6,000
Q1 2023 May 12, 2023	SELL	$8.88 - $12.11 $4,963 - $6,769	-559 Reduced 50.63%	545 $5,000
Q4 2022 Feb 08, 2023	SELL	$9.86 - $14.59 $110,067 - $162,868	-11,163 Reduced 91.0%	1,104 $11,000
Q3 2022 Nov 10, 2022	SELL	$13.1 - $20.34 $53,094 - $82,438	-4,053 Reduced 24.83%	12,267 $222,000
Q2 2022 Aug 10, 2022	BUY	$12.37 - $21.86 $192,551 - $340,272	15,566 Added 2064.46%	16,320 $231,000
Q1 2022 May 16, 2022	SELL	$15.94 - $23.34 $30,174 - $44,182	-1,893 Reduced 71.51%	754 $17,000
Q4 2021 Feb 14, 2022	BUY	$14.76 - $24.89 $39,069 - $65,883	2,647 New	2,647 $45,000

Others Institutions Holding AURA

# of Institutions

Shares Held

37.6M

Call Options Held

122K

Put Options Held

38.5K

View Full List

About Aura Biosciences, Inc.

Ticker AURA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,273,600
Market Cap $240M
Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develop...

More about AURA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account